Abstract
Exposure to estrogens has been long associated with the genesis of human malignancies, including breast, ovarian, and endometrial cancer. A variety of phase I and II enzymes are involved in the metabolic activation and deactivation of estrogens, including cytochrome P450 isoforms, estrone sulfatase, sulfotransferases, catechol-o-methyltransferase, and uridine-5-diphosphate glucuronosyltransferase. In addition, at least one ATP-binding cassette gene (i.e., ABCG2) is involved in estrogen transport. Variability in the expression levels of these proteins may have important consequences for an individuals susceptibility to certain malignancies. Naturally occurring variants in the genes involved in estrogen exposure levels have been identified that might affect protein function and expression. This review focuses on recent advances in the pharmacogenetics of these proteins, and discusses potential clinical ramifications of these genetic variants.
Keywords: estrogen, metabolism, transport, cancer, pharmacogenetics
Current Drug Metabolism
Title: Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Volume: 4 Issue: 6
Author(s): Nehal J. Lakhani, Jurgen Venitz, William D. Figg and Alex Sparreboom
Affiliation:
Keywords: estrogen, metabolism, transport, cancer, pharmacogenetics
Abstract: Exposure to estrogens has been long associated with the genesis of human malignancies, including breast, ovarian, and endometrial cancer. A variety of phase I and II enzymes are involved in the metabolic activation and deactivation of estrogens, including cytochrome P450 isoforms, estrone sulfatase, sulfotransferases, catechol-o-methyltransferase, and uridine-5-diphosphate glucuronosyltransferase. In addition, at least one ATP-binding cassette gene (i.e., ABCG2) is involved in estrogen transport. Variability in the expression levels of these proteins may have important consequences for an individuals susceptibility to certain malignancies. Naturally occurring variants in the genes involved in estrogen exposure levels have been identified that might affect protein function and expression. This review focuses on recent advances in the pharmacogenetics of these proteins, and discusses potential clinical ramifications of these genetic variants.
Export Options
About this article
Cite this article as:
Lakhani J. Nehal, Venitz Jurgen, Figg D. William and Sparreboom Alex, Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer, Current Drug Metabolism 2003; 4 (6) . https://dx.doi.org/10.2174/1389200033489244
DOI https://dx.doi.org/10.2174/1389200033489244 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design Signal Transduction of Steroidogenic Hormones to the Adrenal and Gonadal Mitochondria and the Possibilities for Combating Lipoid Congenital Adrenal Hyperplasia
Current Signal Transduction Therapy Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma
Current Cancer Therapy Reviews Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Effects of Novel Alkyl Pyridine Platinum Complexes on Apoptosis in Ishikawa Endometrial Cancer Cells
Medicinal Chemistry miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design The Urokinase Receptor Interactome
Current Pharmaceutical Design CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Induced Fit Docking and Automated QSAR Studies Reveal the ER-α Inhibitory Activity of <i>Cannabis sativa</i> in Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Breast Cancer: Not Only a “Womans” Disease
Current Women`s Health Reviews The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design